IMPORTANT: Update on ELEVIDYS for Non-Ambulatory Clients

Date: 06/20/25

Sarepta has announced a temporary suspension of ELEVIDYS (delandistrogene moxeparvovec-rokl)  shipments for non ambulatory patients. In response, Superior HealthPlan’s Pharmacy team will collaborate with affected providers to pause administration of ELEVIDYS for Superior Medicaid (STAR, STAR Health, STAR Kids, STAR+PLUS), CHIP and STAR+PLUS Medicare-Medicaid Plan (MMP) members. Updated guidance and support will beprovided as an enhanced immunosuppressive regimen is under evaluation.

ELEVIDYS is an adeno-associated virus vector-based gene therapy approved for use in both ambulatory and non-ambulatory members, aged four years or older, with Duchenne Muscular Dystrophy (DMD) and a confirmed mutation in the DMD gene.

The Texas Health and Human Services Commission (HHSC) has been notified of this safety update related to ELEVIDYS (HCPCS code J1413) for non-ambulatory patients. HHSC will revise prior authorization criteria as updated guidance becomes available from regulatory authorities.

For further questions or details, contact our Pharmacy Services Help Desk at 1-866-768-7147.